Valuation: Forte Biosciences, Inc.

Market Cap 1.07B 939M 866M 800M 1.52B 102B 1.54B 10.35B 4.06B 50.42B 4.03B 3.94B 173B P/E 2026 *
-10.7x
P/E 2027 * -10.3x
Enterprise Value 1.07B 939M 866M 800M 1.52B 102B 1.54B 10.35B 4.06B 50.42B 4.03B 3.94B 173B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+19.67%
1 week+109.94%
Current month+106.68%
1 month+150.11%
3 months+25.16%
6 months+48.08%
Current year+61.06%
1 week 20.2
Extreme 20.2
45.36
1 month 16.89
Extreme 16.89
45.36
Current year 15.51
Extreme 15.51
45.36
1 year 9.1
Extreme 9.1
45.36
3 years 4.11
Extreme 4.11
45.36
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 31/12/2017
Director of Finance/CFO 59 29/02/2020
Chief Operating Officer - 30/09/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 31/05/2020
Director/Board Member 79 15/03/2022
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Executive Officer

2,598 0.0127%
06-30Fiscal year

Chief Financial Officer

884 0.0043%
06-15Free

Chief Executive Officer

500,000 2.4415%
Change 5-day change 1-year change 3-year change Capi.($)
+19.67%+109.94%+316.30%+73.94% 1.07B
+1.84%-0.66%+59.82%+94.48% 54.88B
-4.14%-8.06%+58.96%+125.71% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
+0.53%+0.53%+42.06%-6.63% 19.87B
-3.19%0.00%+35.60%-27.49% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.32%-2.77%+48.48%+643.07% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average +0.11%+10.74%+78.11%+191.25% 24.26B
Weighted average by Cap. -1.66%-0.96%+52.18%+172.14%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.57M -77.08M -71.19M -135M -9.11B -137M -921M -362M -4.49B -359M -351M -15.43B -130M -114M -105M -97.19M -184M -12.44B -188M -1.26B -494M -6.13B -490M -479M -21.07B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
10/07/26 US$43.92 +19.67% 3,191,577
09/07/26 US$36.70 +78.33% 4,866,491
08/07/26 US$20.58 -7.51% 590,078
07/07/26 US$22.25 +9.02% 500,708
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
43.92USD
Average target price
64.75USD
Spread / Average Target
+47.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock